About Us
World Leaders in Multiplexing Diagnostics
SpeeDx is a leading innovator in molecular diagnostics multiplexing, delivering two complementary solutions: market-leading diagnostic products and bespoke development services. Since 2009, we've pioneered the tests behind Resistance Guided Therapy and advanced multiplexing technologies that empower laboratories, healthcare systems, and diagnostics companies to deliver better patient outcomes. With proprietary technologies backed by 100+ patents, global operations across three continents, and partnerships with industry leaders, we're building the future of molecular multiplexing applications.
Founded in 2009 by molecular biologists Adj. Prof. Alison Todd and Dr. Elisa Mokany, SpeeDx emerged from a vision to push the boundaries of what molecular diagnostics could achieve. What began in Sydney, Australia, has grown into a global organization with additional offices in London and the U.S., serving customers across North America, Europe, Asia-Pacific, and beyond.
As an ISO 13485-certified company with strong financial backing, we've evolved from an innovative startup to an established industry leader. Our journey has been recognized with Australia's highest honors, including the Prime Minister's Prize for Innovation (2022), Australian Company of the Year (2021), and the Clunies Ross Award for Innovation (2020). Under the leadership of CEO Jeremy Stackawitz, whose extensive diagnostics industry experience spans over 25 years, we continue to expand our global footprint while maintaining our commitment to scientific leadership, as well as customer and partner excellence.
What we do
Diagnostic products
Our portfolio of market-ready assays serves reference laboratories and healthcare facilities worldwide. From our industry-leading STI diagnostics—including the pioneering ResistancePlus® line that enables Resistance Guided Therapy—to our comprehensive respiratory testing solutions, we deliver products that go beyond simple detection to provide actionable clinical information. Every assay is designed for real-world laboratory workflows, with flexible instrument compatibility and robust performance validated across diverse testing environments.
Development services
For diagnostics companies, pharmaceutical partners, healthcare systems, and reference labs seeking custom solutions, we offer full-service development capabilities. Our experienced team provides bespoke assay development, technology partnerships, custom components, and strategic joint ventures. We apply multiplexing solutions to transform complex challenges into commercial-ready solutions—faster and more cost-effectively than building in-house capabilities. When you partner with SpeeDx, you gain immediate access to world-class multiplexing technology and decades of combined expertise.
What we do
Research products
Our portfolio of multiplexed assays serve the research needs of laboratories worldwide. From STI tests, to respiratory panels with concise or extended targets, to comprehensive GI testing solutions, as well as more specialized assays – whatever your interest, we have you covered. SpeeDx assays are designed for real-world laboratory workflows, with flexible instrument compatibility. The combination of our cost-effective reagents and a high throughput workflow provides scaled efficiencies suited to your specific requirements.
Development services
For diagnostics companies, pharmaceutical partners, healthcare systems, and reference labs seeking custom solutions, we offer full-service development capabilities. Our experienced team provides bespoke assay development, technology partnerships, custom components, and strategic joint ventures. We apply multiplexing solutions to transform complex challenges into commercial-ready solutions—faster and more cost-effectively than building in-house capabilities. When you partner with SpeeDx, you gain immediate access to world-class multiplexing technology and decades of combined expertise.
Our commitment to innovation is not measured in patents alone, but in tangible improvements to healthcare and beyond
Multiplexing
Leadership
Setting the Global Standard in Multiplex Molecular Diagnostics
Molecular multiplexing—the ability to detect multiple targets simultaneously in a single test—is transforming diagnostics, as it continues to supersede traditional testing methods. SpeeDx doesn't just participate in this transformation; we define it.
Our patented PlexPCR® technology, utilising proprietary PlexZyme® and PlexPrime® innovations, enables high multiplexing capabilities and clustered mutation detection, while maintaining the simplicity and reliability laboratories demand. Our latest breakthrough, PlexPlus® technology, doubles standard qPCR output and is ideal for syndromic testing, which is highlighted by our respiratory panel detecting 14 viral targets in a single well.
More than theoretical innovation, our multiplexing technologies are deployed to laboratories across six continents, processing millions of patient samples annually. Whether you need proven products or custom development, when the conversation turns to multiplexing, it starts with SpeeDx.
At SpeeDx, we are passionate about delivering innovative multiplexed solutions that make a difference. This drive attracts top scientific talent, secures research partnerships with leading institutions, and aligns our priorities with the world’s most difficult and important diagnostic challenges.
The power of SpeeDx
SpeeDx pioneered ResistancePlus® tests that simultaneously detect infectious pathogens and mutations associated with antibiotic resistance.* This approach enables Resistance Guided Therapy and has transformed the management of challenging infections like Mycoplasma genitalium and Neisseria gonorrhoeae, improving cure rates while combating antimicrobial resistance. [1,2]
Resistance Guided Therapy
Partner with us
With a history of proven commercial success, SpeeDx collaborates with the world's most respected names in healthcare and diagnostics. Our partnerships span pharmaceutical leaders developing novel therapeutics, global diagnostic companies expanding their test menus, and labs implementing cutting edge testing strategies.
Our growing global distribution network ensures that laboratories worldwide have access to our innovations, while our direct sales and support teams in key markets provide the access and expertise our partners need.
References:
1. Durukan et. Al. Clin Infect Dis. 2020 Sep 12;71(6):1461-1468
2. Read et. al. Clin Infect Dis. 2019 Feb 1;68(4):554-560
*ResistancePlus products are not available in all regions. For options within your region please reach out to our team today.